Cargando…
Antibody-dependent cellular cytotoxicity against drug-induced antigens in L5178Y mouse lymphoma.
In vivo treatment with antineoplastic compounds has been reported to lead to the expression of new antigenic specificities which were not detected on parental cells, and which were transmissible as a genetic character. The current study is concerned with antibody-dependent cellular cytotoxic (ADCC)...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1982
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2011101/ https://www.ncbi.nlm.nih.gov/pubmed/7150471 |
_version_ | 1782136461122863104 |
---|---|
author | Franco, P. Veronese, F. Levi, F. Goldin, A. Nicolin, A. |
author_facet | Franco, P. Veronese, F. Levi, F. Goldin, A. Nicolin, A. |
author_sort | Franco, P. |
collection | PubMed |
description | In vivo treatment with antineoplastic compounds has been reported to lead to the expression of new antigenic specificities which were not detected on parental cells, and which were transmissible as a genetic character. The current study is concerned with antibody-dependent cellular cytotoxic (ADCC) activity in serum of syngeneic mice challenged with LY/DTIC cells, a subline of LY murine lymphoma, antigenically altered by the drug DTIC. LY/DTIC target cells coated with LY/DTIC-immune serum were specifically lysed by virgin lymphocytes. The genetic background of the effector cells, whether syngeneic, allogeneic or xenogeneic, did not produce significant differences in the percentage of target-cell lysis. ADCC activity was reduced when the immune serum was added directly to the incubation medium, without precoating. Although sera from individual animals exhibited different levels of ADCC activity, they nevertheless followed the general trend of the pooled sera. Peak activity of ADCC was obtained in the sera collected on Days 8 and 30 after LY/DTIC cell challenge. The ADCC activity elicited by LY/DTIC cells may contribute to the rejection of drug-altered tumour cells. |
format | Text |
id | pubmed-2011101 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1982 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-20111012009-09-10 Antibody-dependent cellular cytotoxicity against drug-induced antigens in L5178Y mouse lymphoma. Franco, P. Veronese, F. Levi, F. Goldin, A. Nicolin, A. Br J Cancer Research Article In vivo treatment with antineoplastic compounds has been reported to lead to the expression of new antigenic specificities which were not detected on parental cells, and which were transmissible as a genetic character. The current study is concerned with antibody-dependent cellular cytotoxic (ADCC) activity in serum of syngeneic mice challenged with LY/DTIC cells, a subline of LY murine lymphoma, antigenically altered by the drug DTIC. LY/DTIC target cells coated with LY/DTIC-immune serum were specifically lysed by virgin lymphocytes. The genetic background of the effector cells, whether syngeneic, allogeneic or xenogeneic, did not produce significant differences in the percentage of target-cell lysis. ADCC activity was reduced when the immune serum was added directly to the incubation medium, without precoating. Although sera from individual animals exhibited different levels of ADCC activity, they nevertheless followed the general trend of the pooled sera. Peak activity of ADCC was obtained in the sera collected on Days 8 and 30 after LY/DTIC cell challenge. The ADCC activity elicited by LY/DTIC cells may contribute to the rejection of drug-altered tumour cells. Nature Publishing Group 1982-08 /pmc/articles/PMC2011101/ /pubmed/7150471 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Franco, P. Veronese, F. Levi, F. Goldin, A. Nicolin, A. Antibody-dependent cellular cytotoxicity against drug-induced antigens in L5178Y mouse lymphoma. |
title | Antibody-dependent cellular cytotoxicity against drug-induced antigens in L5178Y mouse lymphoma. |
title_full | Antibody-dependent cellular cytotoxicity against drug-induced antigens in L5178Y mouse lymphoma. |
title_fullStr | Antibody-dependent cellular cytotoxicity against drug-induced antigens in L5178Y mouse lymphoma. |
title_full_unstemmed | Antibody-dependent cellular cytotoxicity against drug-induced antigens in L5178Y mouse lymphoma. |
title_short | Antibody-dependent cellular cytotoxicity against drug-induced antigens in L5178Y mouse lymphoma. |
title_sort | antibody-dependent cellular cytotoxicity against drug-induced antigens in l5178y mouse lymphoma. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2011101/ https://www.ncbi.nlm.nih.gov/pubmed/7150471 |
work_keys_str_mv | AT francop antibodydependentcellularcytotoxicityagainstdruginducedantigensinl5178ymouselymphoma AT veronesef antibodydependentcellularcytotoxicityagainstdruginducedantigensinl5178ymouselymphoma AT levif antibodydependentcellularcytotoxicityagainstdruginducedantigensinl5178ymouselymphoma AT goldina antibodydependentcellularcytotoxicityagainstdruginducedantigensinl5178ymouselymphoma AT nicolina antibodydependentcellularcytotoxicityagainstdruginducedantigensinl5178ymouselymphoma |